# A Study of HS-20122 in Patients With Advanced Solid Tumors

> **NCT06927570** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 1050 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HS-20122

## Key facts

- **NCT ID:** NCT06927570
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 1050 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06927570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06927570, "A Study of HS-20122 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06927570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*